Avience Biomedicals (NSE:AVIENCE) Revenue: ₹ Mil (TTM As of Mar. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:AVIENCE Avience Biomedicals Ltd NSE:AVIENCE
18 GF Score
Price ₹250.90
! 3 Warning Signs
View Full Analysis

What is Avience Biomedicals Revenue?

Avience Biomedicals NSE:AVIENCE +1.17% 18 Revenue is ₹ Mil as of Mar. 2025. GuruFocus rates NSE:AVIENCE with a GF Score™ of 18/100. The stock has 3 warning signs investors should review.

Avience Biomedicals's revenue for the six months ended in Mar. 2025 was ₹452.4 Mil. Avience Biomedicals does not have enough years/quarters to calculate its revenue for the trailing twelve months (TTM) ended in Mar. 2025. Avience Biomedicals's Revenue per Share for the six months ended in Mar. 2025 was ₹82.47. Avience Biomedicals does not have enough years/quarters to calculate its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025.

During the past 12 months, the average Revenue per Share Growth Rate of Avience Biomedicals was 88.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

Avience Biomedicals  (NSE:AVIENCE) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.

Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.

Avience Biomedicals Revenue Related Terms

Avience Biomedicals Revenue Historical Data

* Premium members only.

The historical data trend for Avience Biomedicals's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Avience Biomedicals Revenue Chart

Avience Biomedicals Annual Data
Trend Mar23 Mar24 Mar25
Revenue
109.21 239.64 452.36

Avience Biomedicals Semi-Annual Data
Mar23 Mar24 Mar25
Revenue 109.21 239.64 452.36

NSE:AVIENCE vs ABT, SYK, MDT: Revenue Comparison

For the Medical Devices subindustry, Avience Biomedicals's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Avience Biomedicals Revenue vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Avience Biomedicals's Revenue distribution charts can be found below:

* The bar in red indicates where Avience Biomedicals's Revenue falls into.


NSE:AVIENCE
18GF Score
Avience Biomedicals Ltd NSE:AVIENCE
Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Avience Biomedicals Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Frequently Asked Questions Learn more about Revenue →
What does a Revenue of ₹ Mil mean?
Avience Biomedicals (NSE:AVIENCE) has a Revenue of ₹ Mil as of Mar. 2025. Revenue is the total amount a company generates as sales through its operations. View historical data on Avience Biomedicals and its competitors.
Is Avience Biomedicals' Revenue too high?
Avience Biomedicals' current Revenue is ₹ Mil. Overall, Avience Biomedicals has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Avience Biomedicals' Revenue compare to ABT and SYK?
Avience Biomedicals' Revenue of ₹ Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Medical Devices & Instruments company?
A good Revenue depends on the Medical Devices & Instruments industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Avience Biomedicals and its competitors. Avience Biomedicals's current Revenue is ₹ Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avience Biomedicals stock overvalued right now?
Avience Biomedicals (NSE:AVIENCE) has a current Revenue of ₹ Mil. The current Revenue is ₹ Mil. Avience Biomedicals' overall GF Score™ is 18/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Avience Biomedicals (NSE:AVIENCE), the current Revenue is ₹ Mil as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Avience Biomedicals Business Description

Address C-11, Block-C, Community Centre, Unit No-2, 1st Floor, Janakpuri A-3, New Delhi, IND, 110058
Avience Biomedicals Ltd is a medical consumables company focused on the manufacturing of Vitro-Diagnostic (IVD) products and medical devices. Its product offerings include diagnostic solutions used for the detection of diseases, conditions, and infections across laboratory, healthcare, and home-use applications. The company operates in areas including molecular biotechnology, genomics, and diagnostic products, and also provides distribution services for medical technology products in India. Its revenue is generated from Manufactured Goods and Traded Goods and Services, which include the sale of Medical Devices and Consumables.
18GF Score

Get the complete analysis for NSE:AVIENCE

Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹250.90
Price